PFE - Second Death - Pfizer Reports Young Boy's Death After One Year Of Gene Therapy Treatment In Muscle Wasting Disorder Trial | Benzinga
A young patient died due to cardiac arrest after receiving Pfizer Inc’s (NYSE:PFE) experimental gene therapy in a mid-stage trial for Duchenne muscular dystrophy (DMD), the company told in a letter to Parent Project Muscular Dystrophy.
The boy was enrolled in Phase 2 DAYLIGHT study studying the treatment in boys at least two years old and under four years old.
The patient received the investigational gene therapy, fordadistrogene movaparvovec (PF-06939926), in early 2023.
Citing Pfizer, Reuters highlighted that the boy died of cardiac arrest but that it was still working to understand what happened and the exact cause.
All participants ...